News
InvestorsHub on MSN29m
Cognition Therapeutics Shares Surge After FDA Confirms Phase 3 Trial Design
Cognition Therapeutics Inc (NASDAQ:CGTX) saw its stock jump 27% following FDA confirmation that the company’s proposed Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback